Free and efficient financial markets are essential to a diverse and growing economy. They allow businesses to succeed and individuals to build financial security. To support that system, we need smart regulation that ensures access to capital and credit, enables companies to go public, incentivizes innovation, and provides choice and access for investors while protecting consumers.
U.S. legislative proposals could undermine U.S. economic and security interests and strengthen foreign rivals without any apparent benefit to U.S. consumers.
What small businesses and corporations need to know about financing and financial regulations, including information about accessing credit, raising capital, and the role of government agencies and financial institutions.
- How Bank Mergers Promote CompetitionBank mergers help drive innovation and access to products and services for consumers. But proposed legislation could stifle deals at a time when new technologies and entrants are creating more competition than ever before.
- Why Selling Your Business Might Get HarderProposed antitrust legislation could impact the ability of everyone from individual entrepreneurs to multi-million-dollar companies to be acquired.
- 3 Things You Need to Know About Stock BuybacksWith the potential for new legislative developments, now is a good time to take a closer look at stock buybacks: what they are, what they do, what motivates a company to make investment decisions, and who benefits when companies buy back their stock.
The U.S. Chamber promotes policies that ensure U.S. capital markets remain the fairest, most efficient, and innovative in the world. We advocate for legislation and regulation that strengthens our capital markets, allowing businesses—from the local flower shop to a multinational manufacturer—to mitigate risks, manage liquidity, access credit, and raise capital.
Small business advice from CO—
- InternationalInSTEP: The Ongoing Russia-Ukraine Conflict and Geopolitical ImplicationsMonday, October 0304:00 PM EDT - 05:00 PM EDT
- Health CareHealth ForwardTuesday, October 0401:00 PM EDT - 03:00 PM EDT
- FinanceProlific Regulation: Examining SEC Rulemaking Under the Biden AdministrationThursday, October 0611:00 AM EDT - 11:30 AM EDT
- Sep 24, 2021U.S. Chamber Letter on H.R. 1602, the "Eliminate Barriers to Innovation Act of 2021”
This Hill letter was sent to Ranking Member Patrick McHenry and Representatives Stephen Lynch, Glenn Thompson, Ted Budd, and Warren Davidson on H.R. 1602, the "Eliminate Barriers to Innovation Act of 2021.”
- Sep 22, 2021U.S. Chamber Letter on S. 1787, the “State Antitrust Enforcement Venue Act of 2021”
This Hill letter was sent to Members of the Senate Judiciary Committee opposing S. 1787, the “State Antitrust Enforcement Venue Act of 2021.”
- Sep 21, 2021U.S. Chamber Letter on the FY22 NDAA
This Hill letter was sent to the Members of the U.S. House of Representatives on the Fiscal Year 2022 National Defense Authorization Act (NDAA).
- Sep 20, 2021Antitrust 101: Key Terms and Definitions
Key laws and terms to know about antitrust
- Sep 20, 2021The Role & Responsibility of Antitrust
What antitrust is and what it is not
- Sep 20, 2021America’s Antitrust Laws: Myth vs. Facts
It's important to understand what current antitrust laws are and are not.
- Sep 16, 2021Capital Gains Proposals Will Harm U.S. Competitiveness and Job Creation
- Sep 15, 2021Finance and Financial Regulation Basics for Businesses
What small businesses and corporations need to know about financing and financial regulations.
- Sep 10, 2021Inside the FTC’s Ploy to Quash A BioTech Merger
In Franz Kafka’s The Trial, a man is prosecuted by a remote, inscrutable authority. With the nature of his offense unclear and the court’s jurisdiction ambiguous, the entire process becomes bewildering and interminable. As he navigates a labyrinth of bureaucratic traps, the proceedings themselves “gradually merge into the judgment.” Ultimately, Kafka’s character is deemed guilty, without ever hearing the charges against him or having a chance to defend himself.